Latest Articles
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next - Forbes
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next Forbes
Published: June 21, 2024, 7 a.m.
New insights into molecular mechanisms underlying malignant transformation of endometriosis: BANCR promotes miR-612/CPNE3 pathway activity.
Does LncRNA BANCR promote the malignant transformation of endometriosis by activating the miR-612/CPNE3 pathway?
Published: June 21, 2024, midnight
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer - Cancer Health Treatment News
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer Cancer Health Treatment News
Published: June 20, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today
Published: June 18, 2024, 7 a.m.
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile - Wiley Online Library
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile Wiley Online Library
Published: June 18, 2024, 7 a.m.
FDA approves MSD’s KEYTRUDA for endometrial carcinoma - Pharmaceutical Technology
FDA approves MSD’s KEYTRUDA for endometrial carcinoma Pharmaceutical Technology
Published: June 18, 2024, 7 a.m.
Link copied to clipboard!